Benzothiazole aldose reductase inhibitors

Drugs of the Future

Volumn 23, Issue 5, 1998, Pages 521-529

  Ashizawa, Naoki ^a   Aotsuka, Tomoji ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ALDOSE REDUCTASE INHIBITOR; BENZOTHIAZOLE DERIVATIVE; MINALRESTAT; PONALRESTAT; SG 210; SP 210; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CATARACTOGENESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HYPERGLYCEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031817520     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.05.858358     Document Type: Review

References (51)

1. Kador, P.F., Robinson, W.G. Jr., Kinoshita, J.H. The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol 1985, 25: 691-714.
2. Sarges, R., Dates, P.J. Aldose reductase inhibitors: Recent developments. Prog Drug Res 1993, 40: 99-161.
3. Kinoshita, J.H., Datiles, M.B., Kador, P.F., Robinson, W.G. Jr. In: Diabetes Mellitus, Theory and Practice. Rifkin, H., Porte, D. Jr. (Eds.). Elsevier: New York 1990, 264.
4. Greene, D.A., Lattimer, S.A., Sima, A.A.F. Pathogenesis and prevention of diabetic neuropathy. Diab Metab Rev 1988, 4: 201-21.
5. +. Kidney Int 1992, 41: 778-88.
6. +-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 1986, 35: 1106-8.
7. Tomlinson, D.R., Moriarty, R.J., Mayer, J.H. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes 1984, 33: 470-6.
8. Raskin, P., Rosenstock, J. Aldose reductase inhibitors and diabetic complications. Am J Med 1987, 83: 298-306.
9. Kinoshita, J.H., Nishimura, C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988, 4: 323-37.
10. Low, P.A. Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 1987, 10: 121-8.
11. 1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats: Comparison with aldose reductase inhibitor ONO 2235. Diabetes 1989, 38: 832-8.
12. Cameron, N.E., Cotter, M.A. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: Role of polyol pathway activity. Diabetologia 1992, 35: 1011-9.
13. Tesfamariam, B., Palacino, J.J., Weisbrod, R.M., Cohen, R.A. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993, 21: 205-11.
14. Prous, J.R. Treatment of diabetic complications. In: The Year's Drug News - Therapeutic Targets. Prous Science: Barcelona 1994, 275.
15. Aotsuka, T., Abe, N., Fukushima, K., Ashizawa, N., Yoshida, M. Benzothiazol-2-ylcarboxylic acids with diverse spacers: A novel class of potent, orally active aldose reductase inhibitors. Bioorg Med Chem Lett 1997, 7: 1677-82.
16. Mylari, B.L., Larson, E.R., Beyer, T.A. et al. Novel potent aldose reductase inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1- phtharazineacetic acid (zopolrestat) and congeners. J Med Chem 1991, 34: 108-22.
17. Stribling, D., Brittain, D.R. In: Approaches in Drug Research. Harms, A.F. (Ed.). Elsevier: Amsterdam 1986, 297-313.
18. Itoh, Y., Ao, S., Notsu, Y., Hashimoto, M. Novel aldose reductase inhibitors: Synthesis and structure-activity studies of (3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acids. Drugs Fut 1992, 17: 31-7.
19. Shimazaki, N., Tanaka, H., Kuroda, A., Hashimoto, S. (Fujisawa Pharm.). Preparation of quinazolines as aldose reductase inhibitors. JP 03232885.
20. Aotsuka, T., Hosono, H., Kurihara, T., Nakamura, Y., Matsui, T., Kobayashi, F. Novel and potent aldose reductase inhibitors: 4-Benzyl-and 4-(benzothiazol-2-ylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-2-acetic acid derivatives. Chem Pharm Bull 1994, 42: 1264-71.
21. Ishii, A., Kotani, T., Nagaki, Y. et al. Highly selective aldose reductase inhibitors. I. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J Med Chem 1996, 39: 1924-7.
22. Kotani, T., Ishii, A., Nagaki, Y. et al. Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Chem Pharm Bull 1997, 45: 297-304.
23. Malamas, M.S., Hohman, T.C., Millen, J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methy/]-6-fluorospiro[isoquinoline-4-(1H),3′- pyrrolidine]-1,2′,3,5′(2H)-tetrone and congeners. 1. J Med Chem 1994, 37: 2043-58.
24. Wilson, D.K., Tarle, I., Petrash, J.M., Quiocho, F.A. Refined 1.8 Angstrom structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci USA 1993, 90: 9847-51.
25. Nakano, T., Petrash, J.M. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Biochemistry 1996, 35: 11196-202.
26. Matsui, T., Nakamura, Y., Ishikawa, H., Matsuura, A., Kobayashi, F. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol 1994, 64: 115-24.
27. Ashizawa, N., Yoshida, M., Sugiyama, Y. et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn J Pharmacol 1997, 73: 133-44.
28. Barski, O.A., Gabbay, K.H., Grimshaw, C.E., Bohren, K.M. Mechanism of human aldehyde reductase: Characterization of the active site pocket. Biochemistry 1995, 34: 11264-75.
29. Tanimoto, T., Nishiyama, C. Molecular biology of aldose reductase. Exp Med 1991, 9: 541-7.
30. Feather, M.S., Flynn, T.G., Munro, K.A., Kubiseski, T.J., Walton, D.J. Catalysis of reduction of carbohydrate 2-oxoaldehyde (osones) by mammalian aldose reductase and aldehyde reductase. Biochim Biophys Acta 1995, 1244: 10-6.
31. Ratliff, D.M., Vander Jagt, D.J., Eaton, R.P., Vander Jagt, D.L.. Increased levels on methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: Aldose reductase, glyoxalase I, and glyoxalase II - A clinical research center study. J Clin Endocrinol Metab 1996, 81: 488-92.
32. Beyer-Mears, A., Diecke, F.P.J., Mistry, K., Cruz, E. Comparison of the effects of zopolrestat and sorbinil on lens myo-inositol influx. Pharmacology 1997, 54: 76-83.
33. Yoshida, M., Sugiyama, Y., Akaike, N. et al. Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447 - Minor contribution of nitric oxide. Diabetes Res Clin Pract, in press.
34. Tesfamariam, B., Brown, M.L., Cohen, R.A. Aldose reductase and myo-inositol in endothelial cell dysfunction caused by elevated glucose. J Pharmacol Exp Ther 1992, 263: 153-7.
35. Simpson, L.O. Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Muscle Nerve 1988, 11: 725-44.
36. Smith, D.A., Brown, K., Neale, M.G. Chromone-2-carboxylic acids: Roles of acidity and lipophilicity in drug disposition. Drug Metab Rev 1985-86, 16: 365-88.
37. Beyer-Mears, A., Mistry, K., Diecke, F.P.J., Cruz, E. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Pharmacology 1996, 52: 292-302.
38. Azuma, M., Inoue, E., Oka, T., Shearer, T.R. Proteolysis by calpain is an underlying mechanism for formation of sugar cataract in rat lens. Curr Eye Res 1995, 14: 27-34.
39. Tamai, A., Tanaka, K. The ERG of the streptozotocin-diabetic albino rat. Folia Ophthal Jpn 1973, 24: 847-50.
40. Simonsen, S.E. ERG in diabetics. In: The Clinical Value of Electroretinography. Francois, J. (Ed.). Karger: Basel 1968, 403-12.
41. Oates, P.J. Diabetic nephropathy, renal hemodynamics, and aldose reductase inhibitors. Drug Dev Res 1994, 32: 104-16.
42. Oates, P.J., Ellery, C.A., Goldfarb, S. Hyperfiltration and albuminuria are dose-dependently reduced in diabetic rats by zopolrestat. Diabetologia 1993, 36 (Suppl. 1): Abst 848.
43. Oates, P.J., Ellery, C.A. Aldose reductase inhibitor zopolrestat prevents elevated urinary albumin excretion in diabetic rats. Diabetes 1992, 41 (Suppl. 1): Abst 434.
44. Oates, P.J., Ellery, C.A., Inskeep, P.B., Reed, A.E., Beyer, T.A., Huston, N.J. Zopolrestat dose-dependently inhibits renal hyperperfusion in galactosemic rats. Diabetes 1991, 40(Suppl. 1): Abst 524.
45. + pump activity in diabetic rabbit carotid artery: Reversal by aldose reductase inhibition. Am J Physiol 1993, 265 (Heart Circ Physiol 34): H1189-94.
46. Graier, W.F., Grubenthal, I., Dittrich, P., Wascher, T.C., Kostner, G.M. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 1995, 294: 221-9.
47. Ramasamy, R., Oates, P.J., Schaefer, S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997, 46: 292-300.
48. Inskeep, P.B., Reed, A.E., Ronfeld, R.A. Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharm Res 1991, 8: 1511-5.
49. Inskeep, P.B., Ronfeld, R.A., Peterson, M.J., Gerber, N. Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans. J Clin Pharmacol 1994, 34: 760-6.
50. McCaleb, M.L., Sredy, J., Millen, J., Ackerman, D.M, Dvornik, D. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabet Complications 1988, 2: 16-8.
51. Cameron, N.E., Cotter, M.A., Dines, K.C., Maxfield, E.K., Carey, F. Mirrlees, D.J. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994, 37: 651-63.